The role of PARP Inhibition in Clinical Practice
DNA Damage Response (DDR) and PARP inhibitors are promising but complex therapeutic strategies. Understand why, where and how PARP inhibitors work in clinical practice, and look into the future of targeting DDR with this interactive, free to access e-learning course. Designed to support you in selecting the appropriate treatment strategy with PARP inhibitors in the appropriate patient population and to provide the best possible patient care.
Developed by international experts on the clinical use of PARP inhibitors and targeting DDR:
- Robert L. Coleman, MD, Houston, TX, USA
- Rebecca Dent, MD, FRP, Singapore
- Jonathan A. Ledermann, BSc, MD, FRCP, London, UK
- Eric Pujade-Lauraine, MD, PhD, Paris, France
This course is accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) whose system of credits are recognised by AMA and the Royal College of Physicians and Surgeons of Canada and is endorsed by the Innovative Breast Cancer Research Group (SOLTI), the Gynecological Cancer Group Singapore (GCGS) and the Gynecologic Oncology Trial and Investigation Consortium (GOTIC).
Claim your CME credit after passing an assessment at the end.
Downloadable slides accompany this e-learning for your own use.
A range of educational resources on DDR and PARP inhibition are available at cor2ed.com/ddrandparpi.
AstraZeneca has provided a sponsorship grant towards this independent programme.